Trade Report: The Merck & Co. (MRK) is Barrow Hanley Mewhinney & Strauss LLC’s 10th Largest Position

The Merck & Co. (MRK) is Barrow Hanley Mewhinney & Strauss LLC’s 10th Largest Position

Barrow Hanley Mewhinney & Strauss LLC cut its position in shares of Merck & Co. (NYSE:MRK) by 0.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 26,516,070 shares of the company’s stock after selling 147,441 shares during the period. Merck & Co. makes up approximately 2.3% of Barrow Hanley Mewhinney & Strauss LLC’s investment portfolio, making the stock its 10th largest position. Barrow Hanley Mewhinney & Strauss LLC owned 0.96% of Merck & Co. worth $1,527,592,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of MRK. BlackRock Fund Advisors increased its stake in shares of Merck & Co. by 1.4% in the first quarter. BlackRock Fund Advisors now owns 43,031,080 shares of the company’s stock valued at $2,276,774,000 after buying an additional 578,591 shares during the period. BlackRock Group LTD increased its stake in shares of Merck & Co. by 2.0% in the first quarter. BlackRock Group LTD now owns 27,068,748 shares of the company’s stock valued at $1,432,206,000 after buying an additional 525,220 shares during the period. Geode Capital Management LLC increased its stake in shares of Merck & Co. by 1.5% in the first quarter. Geode Capital Management LLC now owns 23,656,034 shares of the company’s stock valued at $1,249,222,000 after buying an additional 353,474 shares during the period. Boston Partners increased its stake in shares of Merck & Co. by 23.8% in the second quarter. Boston Partners now owns 19,034,299 shares of the company’s stock valued at $1,096,566,000 after buying an additional 3,655,639 shares during the period. Finally, Legal & General Group Plc increased its stake in shares of Merck & Co. by 1.1% in the first quarter. Legal & General Group Plc now owns 13,626,514 shares of the company’s stock valued at $720,986,000 after buying an additional 152,049 shares during the period. 72.93% of the stock is owned by hedge funds and other institutional investors.

Shares of Merck & Co. (NYSE:MRK) traded up 0.61% during mid-day trading on Wednesday, hitting $62.84. The stock had a trading volume of 3,256,225 shares. Merck & Co. has a 12-month low of $47.97 and a 12-month high of $64.00. The stock’s 50-day moving average price is $62.71 and its 200-day moving average price is $58.27. The stock has a market capitalization of $173.77 billion, a price-to-earnings ratio of 34.47 and a beta of 0.68.

Merck & Co. (NYSE:MRK) last posted its quarterly earnings data on Friday, July 29th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.91 by $0.02. Merck & Co. had a return on equity of 23.41% and a net margin of 13.01%. The firm had revenue of $9.84 billion for the quarter, compared to the consensus estimate of $9.79 billion. During the same quarter in the prior year, the business earned $0.86 EPS. The business’s revenue for the quarter was up .6% compared to the same quarter last year. On average, equities analysts anticipate that Merck & Co. will post $3.75 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be issued a dividend of $0.46 per share. This represents a $1.84 annualized dividend and a yield of 2.95%. The ex-dividend date is Tuesday, September 13th. Merck & Co.’s dividend payout ratio is 101.10%.

Several research firms recently commented on MRK. Argus restated a “buy” rating and issued a $65.00 target price on shares of Merck & Co. in a research report on Wednesday, September 14th. Morgan Stanley set a $60.00 target price on Merck & Co. and gave the company a “hold” rating in a research report on Tuesday, September 13th. Jefferies Group restated a “hold” rating and issued a $56.00 target price (down from $57.00) on shares of Merck & Co. in a research report on Monday, September 12th. Berenberg Bank restated a “hold” rating and issued a $62.00 target price on shares of Merck & Co. in a research report on Sunday, September 11th. Finally, Barclays PLC raised their target price on Merck & Co. from $66.00 to $72.00 and gave the company an “overweight” rating in a research report on Friday, September 9th. One analyst has rated the stock with a sell rating, twelve have given a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of €63.20 ($70.23).

In other Merck & Co. news, Chairman Kenneth C. Frazier sold 392,000 shares of the company’s stock in a transaction on Friday, August 5th. The shares were sold at an average price of €61.81 ($68.68), for a total transaction of €24,229,520.00 ($26,921,688.89). Following the completion of the sale, the chairman now owns 760,877 shares in the company, valued at approximately €47,029,807.37 ($52,255,341.52). The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Weir Mirian M. Graddick sold 40,800 shares of the company’s stock in a transaction on Monday, October 3rd. The shares were sold at an average price of €62.07 ($68.97), for a total transaction of €2,532,456.00 ($2,813,840.00). Following the sale, the insider now owns 128,973 shares of the company’s stock, valued at approximately €8,005,354.11 ($8,894,837.90). The disclosure for this sale can be found here. Company insiders own 0.05% of the company’s stock.

Merck & Co. Company Profile

Related posts

Leave a Comment